Tango Therapeutics Inc. (TNGX)
1.28
-0.09 (-6.57%)
Apr 03, 2025, 12:35 PM - Market open
-6.57% (1D)
| Bid | 1.28 |
| Market Cap | 138.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.19 |
| PE Ratio (ttm) | -1.08 |
| Forward PE | -2.17 |
| Analyst | Buy |
| Ask | 1.29 |
| Volume | 264,292 |
| Avg. Volume (20D) | 854,572.9 |
| Open | 1.28 |
| Previous Close | 1.37 |
| Day's Range | 1.23 - 1.34 |
| 52-Week Range | 1.23 - 12.02 |
| Beta | 0.87 |
About TNGX
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and ...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 3, 2020
Employees 155
Stock Exchange NASDAQ
Ticker Symbol TNGX
Website https://www.tangotx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for TNGX stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 911.67% from the latest price.
Stock ForecastsNext Earnings Release
Tango Therapeutics Inc. is scheduled to release its earnings on May 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-37.45%
Tango Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
